Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma

Parvin F. Peddi, May Cho, Jian Wang, Feng Gao, Andrea Wang-Gillam

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. Materials and methods: A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or three out of every four weeks. Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All patients had previously received gemcitabine, while 40% had also received FOLFIRINOX. Median number of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of 1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response imaging was available in 17 patients and 11 out of the 17 patients (64.7%) had stable disease. Median progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common treatment related toxicities included grade 1 pneumonitis in five patients (25%), grade 3 or 4 neutropenia in three patients (15%), and dehydration resulting in hospitalization in one patient (5%). Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further prospective studies to evaluate extent of benefit after standard therapies have failed.

Original languageEnglish (US)
Pages (from-to)370-373
Number of pages4
JournalJournal of Gastrointestinal Oncology
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Adenocarcinoma
gemcitabine
Pancreatic Neoplasms
130-nm albumin-bound paclitaxel
Therapeutics
Standard of Care
Neutropenia
Dehydration
Disease-Free Survival
Disease Progression
Pneumonia
Hospitalization
Prospective Studies
Survival

Keywords

  • Monotherapy
  • Nab-paclitaxel
  • Pancreatic adenocarcinoma
  • Refractory disease
  • Registry study

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. / Peddi, Parvin F.; Cho, May; Wang, Jian; Gao, Feng; Wang-Gillam, Andrea.

In: Journal of Gastrointestinal Oncology, Vol. 4, No. 4, 01.01.2013, p. 370-373.

Research output: Contribution to journalArticle

Peddi, Parvin F. ; Cho, May ; Wang, Jian ; Gao, Feng ; Wang-Gillam, Andrea. / Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. In: Journal of Gastrointestinal Oncology. 2013 ; Vol. 4, No. 4. pp. 370-373.
@article{974ba6f4af474aadbf77d1e512b1a3d8,
title = "Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma",
abstract = "Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. Materials and methods: A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or three out of every four weeks. Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All patients had previously received gemcitabine, while 40{\%} had also received FOLFIRINOX. Median number of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of 1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response imaging was available in 17 patients and 11 out of the 17 patients (64.7{\%}) had stable disease. Median progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common treatment related toxicities included grade 1 pneumonitis in five patients (25{\%}), grade 3 or 4 neutropenia in three patients (15{\%}), and dehydration resulting in hospitalization in one patient (5{\%}). Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further prospective studies to evaluate extent of benefit after standard therapies have failed.",
keywords = "Monotherapy, Nab-paclitaxel, Pancreatic adenocarcinoma, Refractory disease, Registry study",
author = "Peddi, {Parvin F.} and May Cho and Jian Wang and Feng Gao and Andrea Wang-Gillam",
year = "2013",
month = "1",
day = "1",
doi = "10.3978/j.issn.2078-6891.2013.034",
language = "English (US)",
volume = "4",
pages = "370--373",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "4",

}

TY - JOUR

T1 - Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma

AU - Peddi, Parvin F.

AU - Cho, May

AU - Wang, Jian

AU - Gao, Feng

AU - Wang-Gillam, Andrea

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. Materials and methods: A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or three out of every four weeks. Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All patients had previously received gemcitabine, while 40% had also received FOLFIRINOX. Median number of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of 1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response imaging was available in 17 patients and 11 out of the 17 patients (64.7%) had stable disease. Median progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common treatment related toxicities included grade 1 pneumonitis in five patients (25%), grade 3 or 4 neutropenia in three patients (15%), and dehydration resulting in hospitalization in one patient (5%). Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further prospective studies to evaluate extent of benefit after standard therapies have failed.

AB - Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. Materials and methods: A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or three out of every four weeks. Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All patients had previously received gemcitabine, while 40% had also received FOLFIRINOX. Median number of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of 1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response imaging was available in 17 patients and 11 out of the 17 patients (64.7%) had stable disease. Median progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common treatment related toxicities included grade 1 pneumonitis in five patients (25%), grade 3 or 4 neutropenia in three patients (15%), and dehydration resulting in hospitalization in one patient (5%). Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further prospective studies to evaluate extent of benefit after standard therapies have failed.

KW - Monotherapy

KW - Nab-paclitaxel

KW - Pancreatic adenocarcinoma

KW - Refractory disease

KW - Registry study

UR - http://www.scopus.com/inward/record.url?scp=84995767418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995767418&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2013.034

DO - 10.3978/j.issn.2078-6891.2013.034

M3 - Article

AN - SCOPUS:84995767418

VL - 4

SP - 370

EP - 373

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 4

ER -